Serum and vitreous resistin levels in patıents with proliferative diabetic retinopathy

• Published in: Diabetes research and clinical practice 2019-09, Vol.155, p.107803-107803, Article 107803
• Main Authors: Gurlevik, Ugur, Ozdamar Erol, Yasemin, Yasar, Erdogan
• Format: Article
• Language: English
• Subjects: Adipokine; Proliferative diabetic retinopathy; Resistin; Vitreous
• ISSN: 0168-8227; 1872-8227
• DOI: 10.1016/j.diabres.2019.107803

The aim of the study was to investigate the serum and vitreous levels of resistin in patients with the proliferative diabetic retinopathy (PDR) and to compare those with age-matched control subjects. The study included 45 eyes with PDR (group 1) and a control group of 22 (group 2). All eyes underwent vitrectomy surgery. The lipid profile, fasting blood glucose (FBG), HbA1c and resistin levels were investigated in blood samples of all subjects. Complete ophthalmological examinations were evaluated. Vitreous samples were collected from both groups during vitrectomy surgery and resistin levels were investigated in those samples. The results were evaluated using SPSS 9.0 software. The demographic characteristics of the diabetic group and the control group were similar (p > 0.05). There was no significant difference between the groups in respect of mean visual acuity (VA), body mass index (BMI) values, or lipid profiles (p ˃ 0.05). There was no measurable value of resistin in the vitreous samples of all the eyes. The mean blood resistin level was 367 ng/ml in the control group and 387 ng/ml in the study group and the difference was not statistically significant (p > 0.05). In the light of the findings of this study, it can be assumed that resistin did not pass through the vitreous at measurable levels. However, the serum resistin levels of the diabetic patients were higher than those of the control group although not statistically significant. Therefore, it can be considered that resistin does not play a major role in retinal neovascularization.